Consequences of chromsome18q deletions. (3rd August 2015)
- Record Type:
- Journal Article
- Title:
- Consequences of chromsome18q deletions. (3rd August 2015)
- Main Title:
- Consequences of chromsome18q deletions
- Authors:
- Cody, Jannine D.
Sebold, Courtney
Heard, Patricia
Carter, Erika
Soileau, Bridgette
Hasi‐Zogaj, Minire
Hill, Annice
Rupert, David
Perry, Brian
O'Donnell, Louise
Gelfond, Jon
Lancaster, Jack
Fox, Peter T.
Hale, Daniel E.
Cody, Jannine DeMars
Battaglia, Agatino
Hale, Daniel Esten - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajmgc31446-sec-0001" sec-type="section"> <p>Providing clinically relevant prognoses and treatment information for people with a chromsome18q deletion is particularly challenging because every unrelated person has a unique region of hemizygosity. The hemizygous region can involve almost any region of 18q including between 1 and 101 genes (30 Mb of DNA). Most individuals have terminal deletions, but in our cohort of over 350 individuals 23% have interstitial deletions. Because of this heterogeneity, we take a gene by gene approach to understanding the clinical consequences. There are 196 genes on 18q. We classified 133 of them as dosage insensitive, 15 (8%) as dosage sensitive leading to haploinsufficiency while another 10 (5%) have effects that are conditionally haploinsufficient and are dependent on another factor, genetic or environmental in order to cause an abnormal phenotype. Thirty‐seven genes (19%) have insufficient information to classify their dosage effect. Phenotypes attributed to single genes include: congenital heart disease, minor bone morphology changes, central nervous system dysmyelination, expressive speech delay, vesicouretreral reflux, polyposis, Pitt‐Hopkins syndrome, intellectual disability, executive function impairment, male infertility, aural atresia, and high frequency sensorineural hearing loss. Additionally, identified critical regions for<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajmgc31446-sec-0001" sec-type="section"> <p>Providing clinically relevant prognoses and treatment information for people with a chromsome18q deletion is particularly challenging because every unrelated person has a unique region of hemizygosity. The hemizygous region can involve almost any region of 18q including between 1 and 101 genes (30 Mb of DNA). Most individuals have terminal deletions, but in our cohort of over 350 individuals 23% have interstitial deletions. Because of this heterogeneity, we take a gene by gene approach to understanding the clinical consequences. There are 196 genes on 18q. We classified 133 of them as dosage insensitive, 15 (8%) as dosage sensitive leading to haploinsufficiency while another 10 (5%) have effects that are conditionally haploinsufficient and are dependent on another factor, genetic or environmental in order to cause an abnormal phenotype. Thirty‐seven genes (19%) have insufficient information to classify their dosage effect. Phenotypes attributed to single genes include: congenital heart disease, minor bone morphology changes, central nervous system dysmyelination, expressive speech delay, vesicouretreral reflux, polyposis, Pitt‐Hopkins syndrome, intellectual disability, executive function impairment, male infertility, aural atresia, and high frequency sensorineural hearing loss. Additionally, identified critical regions for other phenotypes include: adolescent idiopathic scoliosis and pectus excavatum, Virchow‐Robin perivascular spaces, small corpus callosum, strabismus, atopic disorders, mood disorder, IgA deficiency, nystagmus, congenital heart disease, kidney malformation, vertical talus, CNS dysmyelination growth hormone deficiency and cleft palate. Together these findings make it increasingly feasible to compile an individualized syndrome description based on each person's individuated genotype. Future work will focus on understanding molecular mechanisms leading to treatment. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- American journal of medical genetics. Volume 169:Number 3(2015:Jul.)
- Journal:
- American journal of medical genetics
- Issue:
- Volume 169:Number 3(2015:Jul.)
- Issue Display:
- Volume 169, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 169
- Issue:
- 3
- Issue Sort Value:
- 2015-0169-0003-0000
- Page Start:
- 265
- Page End:
- 280
- Publication Date:
- 2015-08-03
- Subjects:
- Medical genetics -- Periodicals
616.04205 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/ajmg.c.31446 ↗
- Languages:
- English
- ISSNs:
- 1552-4868
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0827.940000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4374.xml